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The  rapid  development  of  puriﬁcation  processes  for polysaccharide  vaccines  is constrained  by a lack  of
analytical  tools  current  technologies  for the  measurement  of  polysaccharide  recovery  and  process-related
impurity  clearance  are complex,  time-consuming,  and generally  not  amenable  to  high  throughput  process
development  (HTPD).  HTPD  is envisioned  to be  central  to the  improvement  of  existing  polysaccharide
manufacturing  processes  through  the  identiﬁcation  of critical  process  parameters  that  potentially  impact
the  quality  attributes  of  the  vaccine  and  to  the  development  of  de  novo processes  for  clinical  candidates,
across  the  spectrum  of  downstream  processing.  The  availability  of  a fast and  automated  analytics  platform
will  expand  the  scope,  robustness,  and  evolution  of Design  of  Experiment  (DOE)  studies.
This  paper  details  recent  advances  in improving  the  speed,  throughput,  and  success  of  in-process  ana-
lytics  at  the micro-scale.  Two  methods,  based  on  modiﬁcations  of  existing  procedures,  are  described
for  the rapid  measurement  of  polysaccharide  titre in  microplates  without  the  need  for heating  steps.  A
simpliﬁcation  of  a commercial  endotoxin  assay  is also  described  that features  a single  measurement  at
room  temperature.  These  assays,  along  with  existing  assays  for protein  and  nucleic  acids  are  qualiﬁed  for
deployment  in  the  high  throughput  screening  of polysaccharide  feedstreams.  Assay  accuracy,  precision,
robustness,  interference,  and ease  of  use  are  assessed  and  described.  In  combination,  these  assays  are
capable  of measuring  the  product  concentration  and  impurity  proﬁle  of  a microplate  of 96  samples  in less
than  one  day.  This  body  of  work  relies  on  the  evaluation  of  a combination  of  commercially  available  and
clinically  relevant  polysaccharides  to ensure  maximum  versatility  and  reactivity  of  the  ﬁnal  assay  suite.
Together,  these  advancements  reduce  overall  process  time  by up  to  30-fold  and  signiﬁcantly  reduce  sam-
ple  volume  over  current  practices.  The  assays  help  build  an  analytical  foundation  to  support  the  advent
of  HTPD  technology  for polysaccharide  vaccines.  It is envisaged  that this  will  lead  to an  expanded  use  of
Quality  by  Design  (QbD)  studies  in  vaccine  process  development.
ublis©  2014  The  Authors.  P
. Introduction
The worldwide vaccine market is experiencing unprecedented
rowth. In 2009, the worldwide vaccine market was  valued at $22.1
illion and was expected to grow to >$40 billion by 2015 [1,2]. The
trength of the vaccines segment has revived investment in vac-
ine research and development and has led to numerous vaccine
andidates entering the industrial development pipeline [3]. Multi-
alent polysaccharide vaccines will form an increasingly prominent
hare of future approved vaccines [3–5]. This class of vaccines
∗ Corresponding author. Tel.: +44 020 7679 0438; fax: +44 020 7916 3943.
E-mail address: ucbetkm@ucl.ac.uk (T. Mukhopadhyay).
ttp://dx.doi.org/10.1016/j.vaccine.2014.02.034
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/3.0/).
incorporates several different polysaccharide serotypes in the drug
product in order to confer broad protection against the diverse
strains of infectious agents.
Manufacturing processes for multivalent polysaccharide vac-
cines are complex and expensive. Several different fermentation
and puriﬁcation processes must be developed and operated to
produce material for a single product. Fortuitously, commonali-
ties across a pathogen’s polysaccharide serotypes reveal untapped
potential for the creation of modular development and production
approaches. A directed, modular approach to the rapid develop-
ment of production processes for capsular polysaccharides at the
micro-scale would greatly enhance productivity and speed the
development of novel vaccines. This forms the motivation for the
present study.
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Table 1
Release assays for polysaccharide-containing vaccines [8–15,43].
Target Assay Limitations
Polysaccharide Subunit Highly speciﬁc, typically
time-consuming, requires large
amounts of polysaccharides,
and  subject to substantial
interference
Protein  Lowry Incompatible with most
detergents
Endotoxin  Rabbit injections Animal models, expensive,
time-consuming
Endotoxin  LAL Interference of enzyme
cascade,  ﬁckleness of kinetic820 A. Noyes et al. / Vacc
.1. Capsular polysaccharide biology
Capsular polysaccharides (CPS) form the outer layer of bacterial
ell envelopes. These heterogeneous polymers exhibit vast struc-
ural diversity but are generally composed of monosaccharides
oined through glycosidic and phosphodiester bonds into repeating
ligosaccharide units [6]. Native capsular polysaccharides comprise
ens to thousands of oligosaccharide ‘monomers’ linked together,
anging from kDa to MDa  in molecular weight (MW).  The underly-
ng oligosaccharide repeat unit can be speciﬁc to particular bacterial
pecies, to differentiated serotypes within a species, or even to
tructurally differentiated strains [7]. While the particular consti-
utional monosaccharide(s) are often conserved within a species,
he oligosaccharide structure can differ markedly. In addition, due
o the large number of hydroxyls on each oligosaccharide, cova-
ent bonds can form at an array of locations, resulting in a highly
omplex and variable macromolecular structure.
.2. High throughput processing impediments
Currently, high throughput processing development (HTPD) of
olysaccharide vaccines is rarely practiced, primarily due to a lack
f suitable high throughput analytics. Most of the pertinent pub-
ished analytical literature encompasses methods assessing small
olecules, proteins, or nucleic acids. Limited research has been
resented on the high throughput quantitation of polysaccharides.
oreover, the compatibility of polysaccharides with various high
hroughput technology and the implicit methodological assump-
ions have not been tested. A major bottleneck is the identiﬁcation
f relevant product assays that can be performed in a highly auto-
ated fashion and that are resilient to the diverse conditions
ypically found in developmental studies.
.3. Unique requirements for puriﬁcation process development
Assays to support puriﬁcation process development have
ontrasting demands compared to those for release testing. In
uriﬁcation development, feedstocks are usually in short supply so
olume requirements for the assays must be minimal. Second, the
ssay should ideally be microplate-based so as to facilitate paral-
el processing. The assays should be simple, straightforward and
apid as multiple assays may  be performed to support a single
creen. Integration with robotic liquid handling systems and the
ypical room temperature environment of the robots is also desired.
nother signiﬁcant issue is assay interference because in-process
amples typically have high levels of impurities that can interfere
ith assays. When combined with lower polysaccharide titres than
re found in pure drug substance, this puts stringent demands on
ssay robustness. Fortunately, the requirements for accuracy are
ess stringent than for a release assay. Moreover, as puriﬁcation
TPD favours the screening of puriﬁcation conditions in a 96-well
icroplate, the precision of an assay is often more important than
he accuracy. The results from a single screen are compared only
ithin the screen, and the best conditions are subsequently veriﬁed
ith a scaled up process.
.4.  Analytics
.4.1. Current practice
Most  vaccine release assays are speciﬁed by the World Health
rganization (WHO) or Pharmacopoeia organizations and have not
hanged much in decades. The relevant established assays and
ey drawbacks are highlighted in Table 1. While these assays are
uitable and highly accurate for the release testing of highly con-
entrated, relatively pure formulations, they are poorly suited for
ntegration in a high throughput puriﬁcation context.measurements,  requirement of
specialized equipment
Typical vaccine release speciﬁcations and in-process con-
centrations provide insight into analytical requirements. The
European Pharmacopeia and WHO  release speciﬁcations for pro-
tein and DNA levels in polysaccharide-containing vaccines do not
require exhaustively sensitive analytics. With release speciﬁca-
tions generally ≤1–3% (w/w CPS) protein or DNA and ≤100 IU/mg
polysaccharide for endotoxin, detecting minute quantities of impu-
rities is not necessary [8–15]. The conclusion is similar for titre
measurements, where in-process polysaccharide concentrations
typically range from 0.1 to 10 mg/mL. In this context, quantifying
much less than 0.01 mg/mL  holds diminishing value. This latter
point is driven in part by the modest equilibrium puriﬁcation
factors that can be expected from a single stage puriﬁcation exper-
iment performed in a microwell.
1.4.2. Sugar assays
The  consistent measurement of polysaccharide quantity may
prove the most challenging measurement. The published assays
available for capsular polysaccharides typically quantify a spe-
ciﬁc subunit of the repeating structure. Hence, each capsular
polysaccharide or subset of serotypes tends to have a custom
method for polysaccharide quantiﬁcation. Many of these assays
involve complex colorimetric procedures but research groups have
found alternative approaches for measuring polysaccharide quan-
tity [16–18].
Several authors have recognized the analytical bottleneck posed
by sugar quantitation and devised high throughput methods.
Methods based on anthrone have been developed and further
scaled-down to microplates [17–19]. This assay’s limitations
include reagent instability, poor reactivity with pentoses and
methylated sugars, interference by process substance such as phe-
nol, and issues with consistency [20,21]. Refractive index has been
used in conjunction with HPLC for many years to estimate sugar
content. However, without the added puriﬁcation and normaliza-
tion provided by chromatography, this approach is exceedingly
sensitive to background interference. Other methods involving
phenol, 1-napthosulfonate, or aniline phthalate/trichloroacetic
acid  have been proposed but suffer from toxicity, interference, and
limited reactivity with ketoses, respectively [20].
The phenol sulphuric acid method (PHS) is perhaps the most
promising assay for integration with high throughput screening.
This method is based on a colorimetric product formed when phe-
nol, sulphuric acid, and sugar are reacted and was ﬁrst described
by Dubois et al. in 1951 [22]. This assay is broadly applicable
and measures hexoses and pentoses in a variety of oligosaccha-
rides, making it useful for quantifying neutral sugars [20,23]. The
broad carbohydrate speciﬁcity of this assay underlies its attractive-
ness but the measurement may  be confounded by the reaction of
heterogeneous carbohydrate-containing substances, such as gly-
coproteins. In one modiﬁcation on the original method, the PHS
ine 32 (2014) 2819–2828 2821
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Fig. 1. Analytical workﬂow to support HTPD. The full suite of analytics can be com-A. Noyes et al. / Vacc
rocedure was reﬁned by reversing the sequence of reagent addi-
ion to improve sensitivity for glycated proteins and uniformity
ith respect to sugar type [24]. Saha et al. removed the heat-
ng step and reduced volumes to 2.5 mL  total per sample [25].
ubsequent efforts have focused on reducing the volume fur-
her and/or improving throughput but have required cumbersome
eating and/or specialized pipetting not amenable to automation
25–28]. To further optimize and minimize interference, proce-
ures for cleaning up protein interference have been described
29,30]. However, none of the described methods minimize sample
tilization nor are microplate-based, while concurrently simplify-
ng the heating procedures sufﬁciently for transfer to a robot for
utomation.
.4.3. Impurity assays
Rapid  impurity measurements are critical for the develop-
ent of puriﬁcation processes from biological feedstreams. Assays
or impurities such as protein, DNA, and endotoxin are typically
aborious and lack adequate robustness when used in complex
ackgrounds.
Endotoxin assays have historically been enzymatic, time-
onsuming, and rarely automated. A recent addition to the panel
f commercially available assays offers promise for rapid detec-
ion [31]. The PyroGeneTM assay utilizes a recombinant protease
ymogen, Factor C that is activated upon endotoxin binding. The
ctivated enzyme then cleaves a ﬂuorogenic substrate, which emits
ight at 440 nm when excited at 380 nm.  As opposed to kinetic
ssays based on Limulus amebocyte lysate (LAL), the PyroGeneTM
ssay is an endpoint assay.
For  protein quantitation, bicinchoninic acid (BCA) and
oomassie Blue assays for protein concentration can be readily
erformed in a microplate format [32,33]. In the BCA assay,
roteins reduce Cu+2 to Cu+1 in alkaline conditions. A proprietary
CA-containing reagent then reacts with the cuprous ion to form
 purple colour, absorbing at 562 nm [33]. The extent of reaction
epends on the macromolecular structure, number of peptide
onds, and the amount of C, Y, and W residues in the protein
34]. The Bradford assay employs an acidic solution of Coomassie
rilliant Blue G-250 that absorbs at 595 nm when incubated with
roteins containing basic and aromatic residues [35–37]. In this
tudy, the Lowry assay was not tested due to its relative complex-
ty, the multitude of substances (e.g. detergents) that interfere,
nd poor reagent stability [38].
Several high throughput methods exist for measuring DNA con-
entration. Simple methods based on either absorbance at 260 nm
r the ratio of absorbance at 260 nm and 280 nm are excellent for
elatively pure samples. Where a complex absorbance background
recludes the use of absorbance measurements for DNA quantita-
ion, ﬂuorescent assays with Picogreen have proven exceptionally
seful [39].
.4.4.  Interference
Central to the intelligent deployment of assays is an understand-
ng of interference. The process streams created by unit operations
ccurring immediately downstream of a bacterial fermentor may
ave impurities with concentrations 10–100 fold higher than that
f the product. Challenges also exist downstream of the ﬁrst major
uriﬁcation unit operation where impurity loadings can still exceed
he product concentration. Although the levels of interference ease
urther downstream, the potential presence of high concentrations
f added excipients can impair assays. Therefore, a thorough inves-
igation of the proposed assays for interference is critical to the
uccess of high throughput process development.pleted in less than one day and requires less than 300 L, the volume of a standard
96-well  microplate.
1.5. Aims
This study describes the development of rapid and simple assays
to enable the evolution of HTPD for the generation of novel puriﬁ-
cation processes. More speciﬁcally, we describe a set of analytical
methods that will yield information on polysaccharide titre and
impurity amount (i.e. endotoxin, nucleic acids, protein). Emphasis
was given to developing methods that were versatile and would
accommodate many different feedstreams, so as to facilitate future
integration in a potential platform puriﬁcation process. A schematic
of the ﬁnal analytical scheme is given in Fig. 1.
2. Materials and methods
2.1.  Materials
All  common chemicals were commercial analytical grade.
Lysozyme from chicken egg white, albumin from bovine serum
(BSA), l-arabinose, glycogen from oyster, chondroitin sulfate
A sodium salt from bovine trachea, -lactose monohydrate,
glucose,  N-acetyl neuraminic acid from Escherichia coli, Type II -
carrageenan, 3-(N-morpholino)propanesulfonic acid (MOPS), and
dextran were obtained from Sigma-Aldrich (United Kingdom).
Deoxyribonucleic acid (DNA) sodium salt from salmon sperm was
purchased from Fisher Bioreagents (United Kingdom). Sodium algi-
nate from Laminaria hyperborea came from BDH (United Kingdom).
Lonza Walkersville (Maryland, USA) provided endotoxin derived
from E. coli. Gellan gum was  produced by Applichem Biochem-
ica (United Kingdom). High molecular weight hyaluronan (HA)
was purchased from R&D Systems (United Kingdom). Endotoxin
standards and stocks were purchased from Lonza Walkersville
(Maryland, USA). All reagents were used as purchased. All sug-
ars are D isomers except where noted otherwise. Solutions were
ﬁltered with 0.22 m ﬁlters (GV PVDF, PES Express, Millipore,
Massachusetts, USA) where appropriate. Polystyrene microtitre
plates (Corning Costar #3596, Massachusetts, USA) were used
with all assays, except where noted otherwise. All spectroscopic
measurements were made with a Saﬁre II spectrophotometer
(Tecan, Switzerland). Standard abbreviations for l-arabinose (Ara),
ribose (Rib), glucose (Glc), galactose (Gal), glucuronic acid (GlcA),
guluronic acid (GulA), N-acetyl neuraminic acid (NeuNAc), man-
nose (Man) were selectively used to reduce graphical clutter.
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Fig. 2. Glucose standard curves generated with variants of PHS assay, prepared
in  triplicate. ‘Masuko’ refers to method described in Masuko et al. ‘Saha’ refers
to  method described in Saha et al. ‘Current Work’ refers to method as described
in  Section 2, and ‘Current Work*’ is equivalent to ‘Current Work’ but reacted in a
glass instead of a polystyrene microplate [20,25,26]. The volumes prescribed in the822 A. Noyes et al. / Vacc
.2. Absorbance spectra
Absorbance  spectra of pure carbohydrates and proteins were
easured in solutions buffered with 20 mM MOPS, pH 7.2. Spectral
easurements were also recorded following reaction in several col-
rimetric assays. Absorbance spectra were measured from 230 to
000 nm in ≤3 nm increments using the microplate reader.
.3. Bradford assay
The  Bio-Rad protein assay (California, USA) based on Bradford’s
ethod was employed to measure protein concentration [36,37].
he instructions provided by the reagent manufacturer (version:
it 33 Rev C) were followed. Samples were diluted in 20 mM
OPS, pH 7.0. Absorbance measurements were made at 595 nm
nd 990 nm.  Blank-corrected standard curves were run in triplicate
ith absorbance at 990 nm subtracted from absorbance at 595 nm.
inear regression was used to ﬁt the standard curve.
.4. Bicinchoninic acid assay
The BCA assay kit (Pierce Thermo Scientiﬁc, Illinois, USA, ver-
ion: 1296.7) was employed to measure protein concentration [40].
he microplate instructions provided by the assay kit manufacturer
ere followed. Samples were diluted into 20 mM MOPS, pH 7.0.
bsorbance was measured at 562 nm and 990 nm.  Blank-corrected
tandard curves were run in triplicate with a second order polyno-
ial ﬁt employed.
.5.  Phenol sulphuric acid assay
The procedures described by [20,25,26] were used as refer-
nce points to develop a modiﬁed PHS assay. The methods of Saha
t al. formed the basis for the advent of a modiﬁed method as
escribed in Table 2. In the modiﬁed method, 25 L of 5% (m/v)
henol was added to 25 L of sugar solution previously aliquoted
nto the microplate, followed by mixing with a pipettor. Next,
25 L of H2SO4 was added to each well, followed by rapid mix-
ng with a pipettor. Solutions were incubated for 30 min  at room
emperature (18–25 ◦C) before the absorbance was  read at 485 nm
n the microplate reader. Where applicable, samples were diluted
n reverse osmosis-puriﬁed, distilled water. Except for the com-
arative study performed with glucose as a test sample, all PHS
easurements were made with the modiﬁed method. All mixing
as performed via 5 aspiration cycles with a pipette. Standard
urves were run in triplicate with absorbance values corrected for
he blank. The ﬁnal yellow colour was found to be stable for 1 h,
lthough slight development occurred with prolonged incubation
ollowing the reaction. Phenol solution was stored in the dark when
ot in use.
In  certain circumstances with the modiﬁed PHS assay, a glass
icroplate (Zinsser, Germany) was evaluated.
.6. PyroGeneTM assay
A pyrogen assay (PyroGeneTM, Lonza, Maryland, USA) based on
ecombinant Factor C for endotoxin was qualiﬁed. The instructions
rovided by the assay kit manufacturer (version: 08299P50-
58U/NV-612/07) were followed except where noted. Pyrogen-free
onsumables including reagent reservoirs, pipette tips, conical
ubes, LAL Reagent Water, and serological pipettes were purchased
rom Lonza Walkersville. Samples were diluted into LAL Reagent
ater. Standard curves were prepared and run in triplicate. For
ssay interference testing and positive product controls, 10 l of a
0 EU/mL standard solution was added to 90 L of sample, yield-
ng a 1 EU/mL reference standard concentration. Endotoxin samplesoriginal citations were followed. Absorbance was normalized to 300 L per well.
Correlation  coefﬁcients for each linear regression ﬁt line were ≥0.99, except for
Current Work*, where R2 = 0.87.
and standards were vortexed vigorously for the prescribed amount
of time. Except where noted otherwise, microplates were incubated
for 1 h at 37 ◦C inside the plate reader prior to reading. The measure-
ment parameters were: excitation wavelength set to 380 ± 20 nm,
emission wavelength set to 440 ± 20 nm,  and an integration time
of 40 s. The log amount of endotoxin present was proportional to
the log change in the relative ﬂuorescent unit (RFU), with second
order polynomial ﬁts offering the most accuracy.
The methodology employed differed from the manufacturer’s
recommendations in two  signiﬁcant ways. A single measurement
was taken approximately 60 min  after the start of incubation at
37 ◦C instead of the recommended two-point measurement. In
addition, incubations at 22 ◦C, 26 ◦C, and 37 ◦C were evaluated for
varying durations during one experiment.
3. Results and discussion
3.1.  Modiﬁed phenol sulphuric acid assay
Several permutations of the original PHS method for sugar quan-
titation have been described. In order to establish a benchmark
and compare the methods to the modiﬁed method described here,
standard curves were generated with each method, using glucose
as the standard carbohydrate (Fig. 2).
As shown in Fig. 2, the absorbance intensity attained for each
method was  very similar, irrespective of the speciﬁc PHS method
employed. This observation suggests that the extent of reaction
in each microwell was  comparable. The Masuko method was
expected to yield higher absorbance values due to a rearrangement
of the reagent addition sequence but these signal increases were
not realized [26]. Therefore it appears that previously observed
sulphonated phenol-mediated attenuation was  either consistent
or insigniﬁcant.
The precision of the reported PHS procedures differed sig-
niﬁcantly. Across the 17–500 g/mL, the mean relative standard
deviation (RSD) for the Saha, optimized PHS, and Masuko assay
were 6%, 10%, and 22%, respectively. While the Saha method exhib-
ited the best precision, it required the most material (i.e. 0.5 mL).
The decreased reproducibility of the Masuko method may be due
to increased sensitivity to unintended variability in the time lapsed
from sulphuric acid addition (i.e. the heat generation step) to the
A. Noyes et al. / Vaccine 32 (2014) 2819–2828 2823
Table  2
Comparison of PHS methods. The ‘proposed’ method is described in more detail in the accompanying text. ‘RT’ refers to room temperature, 18–25 ◦C operation.
Source Dubois et al. Saha et al. Masuko et al. Proposed
Year 1956 1994 2005 2012
Volume (L) 7050 3500 230 175
[Sugar] (g/mL) 5–35 10–100 4–585 10–1000
Method Add 50 L 80% phenol to
2 mL  sugar
Add 0.5 mL 5% phenol to
0.5 mL  sugar
Add 150 L H2SO4 to 50 L sugar Add 25 L 5% phenol to 25 L sugar
Add  5 mL  H2SO4 Add 2.5 mL  H2SO4 Add 30 L 5% phenol Add 125 L H2SO4
Incubate 10 min  Vortex Incubate 5 min  in 90 ◦C water bath Incubate for 30 min at RT
Shake Incubate 30 min  at RT Cool to RT for 5 min  in RT water bath Read UV
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the original PHS papers by DuBois et al. [20]. The absorptivities
measured in the described PHS assay underpinned the spectrum of
dynamic linear ranges depicted in Fig. 5.Cool  in 25–30 ◦C water bath Read UV
Read  UV 
ddition of phenol. In this work, the order of addition was  found to
e important with better precision observed when the heat gener-
tion step was the ﬁnal step, presumably leading to a more uniform
eaction temperature.
A  consistent reaction was generated by careful consideration of
he factors affecting the temperature of reaction. In contrast to the
ethod described here, which uses a polystyrene microtitre plate,
 reduced signal was observed when the glass microplate was used
). This attenuated signal is likely due to the higher thermal conduc-
ivity and speciﬁc heat of borosilicate glass as well as the greater
olume of material contained in the glass microplate relative to
he polystyrene microplate. These factors presumably prevent the
olution from attaining the high temperature required for robust
eaction.
The testing with glucose established that the modiﬁed PHS assay
ad satisfactory accuracy and precision. This method was  compa-
able to the method of Saha et al. and was characterized by superior
recision to the method of Masuko et al. [25,26]. The reproducibility
as particularly strong for higher polysaccharide concentrations,
hich is within the dynamic range most samples derived from
ypical puriﬁcation HTPD will likely reside. The greater simplic-
ty, speed, and ease of automation afforded by the elimination of
he discrete heating steps warranted further development of the
odiﬁed PHS method.
A  diverse library of mono-, di-, and poly-saccharides were
ssayed with the modiﬁed PHS assay. The carbohydrates tested
ncluded glucose, -lactose monohydrate, l-arabinose, maltose,
yaluronic acid, chondroitin sulfate, sodium alginate, gellan gum,
extran, -carrageenan, glycogen, DNA, endotoxin, and N-acetyl
euraminic acid. Initially, absorbance scans of the reacted sam-
le were made to identify the wavelength at which maximum
bsorbance (max) was  measured. The max fell in the range
77–487 nm which corroborates with the range of 480–490 nm
ublished for more limited subsets of carbohydrates [20,25,26]. For
exose sugars (n = 11), the mean max = 485 ± 3 nm and for pentose
ugars (n = 2), the mean max = 477 ± 1 nm.  From this dataset, a ﬁxed
alue of 485 nm was determined to provide robust measurement
f diverse polysaccharides in the modiﬁed PHS assay.
Using a wavelength of 485 nm,  standard curves were generated
or the library of polysaccharides, with the corresponding gradient
unctions provided in Fig. 3. In the modiﬁed PHS assay, hexoses
bsorb more strongly than pentoses at 485 nm.  This order is main-
ained even if the max for pentoses is used for the absorbance
easurement. The anionic polysaccharides absorb far less per unit
ass than do the neutral carbohydrates. In large part, this is due to
he presence of non-signalling anions such as sulfate.
It  has been previously shown that for complex oligosaccha-
ides containing different hexoses, the summed contribution of
he reactive hexoses equates to the approximate reactivity of the
olysaccharide [25]. Moreover, as N-acetyl galactosamine, N-acetyl
lucosamine, and N-acetyl neuraminic acid have been demon-
trated to insigniﬁcantly react in the PHS assay (data not shown),Wipe microplate dry
Read UV
the  contributions of certain structures can be discounted if other
reactive pentoses and hexoses are present [26]. Similarly, the
organic and inorganic anion groups do not signal and can also be
disregarded. After applying these data transformations to oligosac-
charides comprised of similar repeating sugar components, the
absorbance response converges on a single line as a function of
the concentration of particular reactive monosaccharide (Fig. 4).
The data in Fig. 4 can be used to approximate the expected reac-
tivity of diverse carbohydrates. Of the carbohydrate classes tested,
the hexoses produced the highest absorptivity in the modiﬁed PHS
assay. The absorbance of heteropolysaccharides can be approxi-
mated by the addition of the reactive components. However, it was
noted that addition was  imperfect when heteropolysaccharides
composed of both glucuronic acid and glucose were summed, as
the polysaccharide containing both units reacted slightly less than
the sum of the independently generated glucose and glucuronic
acid curves.
To  facilitate appropriate comparisons, the molar absorptivities
of the reactive units are displayed in Table 3. The absorptivity values
in the modiﬁed PHS method are consistent with those described inFig. 3. Gradient functions of standard curves for neutral and anionic hexoses and
pentoses in the modiﬁed PHS assay. The standard curves for the carbohydrate library
were linear with a correlation coefﬁcient >0.95 for each species tested. The legend
describes the repeating monosaccharide for neutral sugars and the charged group
for anionic sugars.
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Fig. 4. Reaction of carbohydrates listed in Fig. 3, plotted as a function of com-
mon reactive sugars. Non-reactive structural components were ignored. R2 > 0.95
for each ﬁt line. Carbohydrates with glucose and galactose were co-plotted as the
relative reactivity of these hexoses was found to be statistically similar when plotted
independently (decoupled data not shown).
Table 3
Molar  absorptivity of reactive sugars in proposed PHS assay. N-acetyl neuraminic
acid  is representative of a non-reactive carbohydrate.
Sugar Molar absorptivity
(AU((mol/mL)(cm)))
Glc and Gal 1.135
Glc/GlcA 1.171
Ara 0.550
Rib 0.279
GlcA 0.198
t
m
l
m
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F
R
Fig. 6. Concentration of interfering species required to effect a 20% shift in the mea-
sured value. Y-axis values assume the desired analyte is 1 mg/mL glucose. 70 mg/mLManA/GulA 0.135
NANA 0.002
Having an elevated lower limit of quantitation (LOQ) is advan-
ageous when monitoring the array of concentrations across a
icroplate where the load material titre is 0.5–5 mg/mL. The loss of
ow-end sensitivity (i.e. <10 mg/L) is acceptable as detecting such
inute concentrations is not practically relevant, particularly in
uriﬁcation HTPD, where concentration changes greater than 100-
old are rarely encountered.
ig. 5. Linear range of quantitation for carbohydrates in modiﬁed PHS assay. All
2 > 0.95 when ﬁt with linear regression. Range is linear up to A485 = 2.0 AU.impurity on the y-axis represents the maximum level that can be measured based
on the limit-of-quantiﬁcation for the assay. The hypothetical trisaccharide glycan is
Glc-Glc-Glc to represent worst-case interference from the glycosylated protein.
Polysaccharide titre measurements will be required in impure
samples possessing a complex background. DNA, protein, and
endotoxin are impurities present in virtually all in-process samples.
Therefore, a key element of the robustness of the any in-process
sugar assay is the propensity of typical impurities to interfere
Fig. 6.
Interference in the modiﬁed PHS assay was minor. As the
assay is colorimetric and designed for in-process samples, a
shift in measurements of ≥20% was deemed to represent sig-
niﬁcant interference. Every sample tested reacted substantially
less strongly than did glucose. Although proteins did not react
strongly, the tested proteins were not glycosylated. Therefore,
based on the reactivity of the constituent glycan, an estimate was
made of the interference posed by a glycosylated 20 kDa pro-
tein possessing one trisaccharide glycan per protein molecule.
The theoretical degree of interference was  slight for this compo-
sition, due to the low molarity of the pendant oligosaccharide.
Based on Fig. 6, only far upstream in the puriﬁcation process
would samples be likely to contain concentrations of interfering
species (i.e. simple sugars from broth/media, DNA) high enough
relative to the target carbohydrate concentration to cause prob-
lematic interference. In such a case, a high throughput desalting
step using a microtitre plate could be utilized to reduce interfer-
ence.
3.2. Protein assays/differential assay for sugar
Two protein assays were screened for suitability for integra-
tion with polysaccharide HTPD: the BCA and Bradford assays. The
standard curves generated with both protein assays exhibited good
ﬁt. For the BCA assay, a R2 > 0.99 for the 0.025–2 mg/mL  range was
achieved with a relative standard deviation of 4%. Second-order
A. Noyes et al. / Vaccine 32 (2014) 2819–2828 2825
Fig. 7. Absorptivity of various carbohydrates in BCA and Bradford assay, with molec-
ular classiﬁcation provided for species reacting in the BCA assay. Standard curves in
both assays were ﬁt with linear regression although second order polynomial ﬁt-
ting produced slightly better ﬁts for the BCA assay. For Bradford and BCA assays, all
curves were characterized by R2 > 0.92 and R2 > 0.98, respectively. * denotes samples
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compared to kinetic assays (e.g. kinetic QCL), the PyroGeneTM assay
was qualiﬁed as the principal endotoxin assay [41]. As displayed inith  absorptivities BLOQ or that did not signal.
olynomial ﬁtting improved the accuracy and the ﬁt. Correcting
or absorbance at 990 nm decreased the precision slightly and was
ot incorporated. With the Bradford assay, the correlation coefﬁ-
ient was found to be a function of the included range. Employing
.025 mg/mL  as the lowest non-zero concentration tested, lin-
arly ﬁt standard curves with an upper range of 0.5, 1.0, and
.0 mg/mL  were generated. The R2 values for these curves were
0.99, >0.98, and >0.95, respectively, with curves based on the
roader ranges overestimating the highest concentrations. Sub-
raction of the absorbance at 990 nm from the absorbance at 595 nm
mproved mean precision from 6% to 3% RSD.
The impact of interfering species on the two assays was
ixed (Fig. 7). Concentrated DNA (5 mg/mL) produced a signiﬁ-
ant response in the Bradford assay but did not react in the BCA
ssay. In the Bradford assay, the relative responses of lysozyme and
SA to DNA yielded a 28-fold and an 11-fold increase respectively,
uggesting that any related interference would be manageable in
 process development scheme. Endotoxin did not react in either
ssay. Similarly, sugars did not exhibit any reactivity in the Bradford
ssay.
Reducing sugars were oxidized in the BCA assay. Monosac-
haride and disaccharide reducing sugars exhibited the highest
bsorptivity with no clear difference between hexoses or pentoses.
olysaccharides offered lower absorptivities, due to the localiza-
ion of the reducing groups at the termini and the low relative
umber of reducing groups per polysaccharide. Indeed, dextran
xhibited negligible reactivity due to the reducing groups being
onﬁned to a limited number of branched termini and representing
 small portion of the total hexoses comprising the polysaccharide.
on-reducing carbohydrates including glycogen, HA, chondroitin
ulfate, N-acetyl neuraminic acid, and sodium alginate did not react
n the BCA assay (data not shown). In the Bradford assay, no carbo-
ydrates except DNA formed absorbing species, although this was
nly substantial at >1 mg/mL, consistent with product literature
37]. An increase in the absorbance at 595 nm due to shifts in the
harged dye equilibria may  underlie this observation [35]. Depend-
ng on whether the carbohydrate or DNA concentration is known,
he Bradford or BCA assay can both be used for measurement of
rotein contained in-process samples.Fig. 8. Effect of incubation temperature on relative ﬂuorescence measurements in
the PyroGeneTM assay. The incubation duration was 1 h. No signiﬁcant differences
in  measurements were noted when the incubation was extended to 2 h.
3.2.1. Differential use of two protein assays
Given the distinct responses of the two proteins assays to reduc-
ing sugars, an effort was made to use this differential signal to
measure the titre of a reducing sugar. First, the capability to sum
the reactive components of multi-component mixtures was  exam-
ined. The slopes of the standard curves for glucose and BSA were
independently measured, with the sum of the two  slopes equalling
1.56 AU/(mg/mL). A standard curve for samples consisting of 50:50
BSA:glucose was  generated and was  characterized by a slope of
1.31 AU/(mg/mL), 18% below the expected value.
In  a subsequent examination of the differential approach, glu-
cose was  spiked to a ﬁnal concentration of 1 mg/mL in solutions
containing from 0.020 to 0.50 mg/mL  BSA. The amount of glucose
was then calculated from the difference of the BCA and Bradford sig-
nal. This was  achieved by using a calibration equation derived from
the BSA standard curve (to measure glucose in units of mg/mL  BSA)
and normalizing by the ratio of the slopes of the glucose and BSA
standard curves. The outcome of these experiments was  an estima-
tion of 0.72 ± 0.15 mg/mL  of glucose. This result was  imprecise and
was signiﬁcantly below the expected concentration of 1 mg/mL.
This trial indicated that the addition of the two assays was not
accurate or robust enough to use for the purpose of estimating sugar
concentrations. It is believed that the high observed variance and
inaccuracy may  be due to additive errors present when using mul-
tiple assay measurements for a single differential measurement.
Equally problematic, since both protein assays react with an inten-
sity that is dependent on the protein composition, if the relative
reactivity of the two assays to a given sample varied sharply, it
would hinder the utilization of this approach. This is particularly
applicable for puriﬁcation development where protein composi-
tions could differ markedly across a microplate. The contrasting
slopes for lysozyme and BSA standard curves when measured in
both protein assays in Fig. 7 provide an indication of the noise that
could be encountered. For these reasons, the differential method for
reducing sugar quantiﬁcation is better suited to samples puriﬁed
to a greater extent, further downstream in the puriﬁcation process.
3.3. Endotoxin assay
Due  to its simplicity and ease of automation, particularly whenFig. 8, the log–log standard curves were consistent and exhibited
good ﬁt with R2 > 0.99 across a range of 0.01–20 endotoxin units
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iig. 9. Interference in the PyroGeneTM assay. Interfering substances were freshly
repared  in depyrogenated LAL Reagent Water and spiked with endotoxin (20 mM
OPS, pH 7.0) to achieve a ﬁnal endotoxin concentration of 1 EU/mL.
EU)/mL. Precision was found to average 7% RSD across the tested
ange. Several incubation temperatures were evaluated in parallel
ith the standard incubation temperature of 37 ◦C (Fig. 8). Lower-
ng the incubation temperature did not have a deleterious effect
n the reproduction of the standard curve. Enabling the incubation
eriod to occur at room temperature is helpful when automating
ssays with liquid-handling robots situated in room temperature
nvironments.
The potential for various substances to interfere with the
yroGeneTM assay was evaluated through positive product con-
rol samples (Fig. 9). In these samples, endotoxin was  spiked to
 ﬁnal concentration of 1 EU/mL in the presence of a concentration
eries of various impurities (i.e. proteins, sugars, and DNA). Chon-
roitin sulfate, DNA, sodium alginate, -carrageenan, and several
nionic capsular polysaccharides (data not shown) inhibited the
yroGeneTM assay. The severity of the inhibition was  high, with
ilutions to <1 g/mL required to abolish the effect. The inhibi-
ion was consistent across assays performed on multiple days with
reshly made solutions, with multi-day variability of ∼27% (data
ot shown). Each of the inhibitors was an anionic polysaccharide
ut other anionic polysaccharides such as HA, gellan gum, and N-
cetyl neuraminic acid did not react, nor did the acidic protein, BSA.
 common structural feature between the DNA, -carrageenan, and
hondroitin sulfate is the presence of sulfates. Every species with sulfate that was tested was found to inhibit the assay, but other
nionic groups did not interfere consistently. For example, none
f the uronic acid-containing polysaccharides reacted except for
odium alginate (and chondroitin sulfate, which also has sulfate
able 4
heoretical measurable endotoxin clearance values in the presence of interfering species.
s  0.01–10 EU/mL.
[Endotoxin] (EU/mL) 
Post-harvest >20,000,000 
Post-primary recovery 20,000  (2014) 2819–2828
groups).  The mechanisms for inhibition are unknown but possibly
due to electrostatic interactions with the zwitterionic endotoxin.
However, inhibition of the recombinant Factor C through the active
site is unlikely as the lipid domain of endotoxin serves as the sub-
strate [41].
Fresh lysozyme artiﬁcially increased the signal intensity of the
PyroGeneTM assay. The dry chemical stock of lysozyme possi-
bly harboured Gram-negative microbes or pyrogenic byproducts.
Unlike with the LAL assay, high molecular weight carbohydrates
such as carrageenan were not found to enhance the PyroGeneTM
assay [42]. Several of the tested substances (i.e. BSA, HA, lysozyme,
and dextran) exhibited apparent enhancement when initially
tested. As these liquid samples had been stored non-sterile at 5 ◦C
for two weeks, fresh stocks were prepared. Using the fresh stocks,
no enhancement was observed, highlighting the importance of mit-
igating potential Gram-negative bacteria contamination. None of
the tested species consistently interfered except for those shown
in Fig. 9.
Utilization of the PyroGeneTM assay will necessitate extensive
dilution (i.e. 10−3–10−4) to eliminate interference from bacterial
feedstreams. The level of dilution will be predicated on the con-
centration and nature of components in the sample background,
with samples upstream in the process requiring greater dilution
than the more puriﬁed streams found further downstream in the
process. Although the magnitude of the inhibition is signiﬁcant,
the PyroGeneTM assay is still suitable for measuring endotoxin
in impure pools. In polysaccharide process streams derived from
Gram negative bacteria, the starting concentrations of endotoxin
are high. These values often exceed 20,000,000 EU/mL (personal
communication from Dr. Bernie Violand; Pﬁzer R&D). However,
the linear range of the PyroGeneTM assay is 0.01–10 EU/mL,
necessitating multiple serial dilutions to fall within the standard
curve. Because of the large difference between the range of the
PyroGeneTM assay and typical endotoxin concentrations, it is pos-
sible to measure adequate LRV of endotoxin, even when factoring
in dilution to eliminate interference (Table 4). With such high
amounts of endotoxin present, dilution to 10−3–10−4 should still
enable the demonstration of 5–6 log removal value (LRV) of endo-
toxin clearance for harvest samples and 2–3 LRV of endotoxin
clearance for polishing steps. Demonstration of adequate clear-
ance may  be hampered in samples taken downstream of polishing
steps.
4. Automation
The capability to automate assays used to inform puriﬁcation
process development is clearly an important attribute. All of the
described assays can be integrated into an automated analyti-
cal platform, enabling multi-faceted characterization of impurity
clearance and product yield in less than one day by a single scientist.
Automation requires an initial upfront investment of effort to reﬁne
but can be indispensable when repeat analyses are required. In
puriﬁcation process development, several high throughput screens
can be run to evaluate different unit operations or distinct modes
within a given unit operation. In addition, multivalent products
such as most capsular polysaccharide vaccines, present the need for
parallel screening between allied polysaccharide feedstreams. The
 Assumes polysaccharide concentration equals 1 mg/mL  and endotoxin assay range
[Endotoxin] with Assay
Dilution  (EU/mL)
Available  Log Removal
Value  (LRV)
2000–20,000 #9>7#6
2–20 #9‘7#3
ine 32
a
t
s
b
5
c
l
c
m
l
f
a
a
t
d
E
t
t
i
d
t
b
t
o
u
q
i
s
o
u
t
r
i
h
T
i
a
n
l
w
d
T
P
r
d
o
v
q
d
o
B
a
o
t
l
r
w
c
c
[
[
[
[
[
[
[
[
[
[A. Noyes et al. / Vacc
vailability of a fast and automated analytics platform will expand
he scope, robustness, and evolution of Design of Experiment (DOE)
tudies. It is envisaged that this will lead to expanded use of Quality
y Design (QbD) approaches in vaccine process development.
.  Conclusion
Currently, the development of puriﬁcation processes for vac-
ine polysaccharides is exceedingly complex, time-consuming, and
aborious. HTPD of polysaccharides has lagged signiﬁcantly behind
urrent developmental archetypes for other biologicals such as
onoclonal antibodies. The lack of simple, high throughput ana-
ytical tools has played a role in hindering the evolution of HTPD
or polysaccharides.
Puriﬁcation process development does not require the exquisite
ccuracy demanded of release assays. Instead, speed, simplicity,
nd precision are paramount. Especially in the context of high
hroughput process development, the desire to ﬁnd the best con-
itions on a microplate, relative to the other wells, is critical.
xcluding afﬁnity separations, the maximum puriﬁcation factor
hat can be achieved in a single-stage equilibrium experiment is
ypically 2 logs, obviating the need for extremely sensitive analyt-
cs. Accuracy is more important in the subsequent scale-up and
emonstration of promising puriﬁcation conditions.
Polysaccharides, endotoxin, proteins, and nucleic acids are
he major components found in harvested bacterial fermentation
roths employed in industrial polysaccharide vaccine manufac-
uring. Their critical importance is underscored by the inclusion
f the respective assays in the batch release package for prod-
ct characterization. In the current work, analytical techniques for
uantifying polysaccharides, endotoxin, and proteins were qual-
ﬁed. In selecting methods, emphasis was given to procedural
implicity, amenability to automation, robustness, and precision
ver accuracy. In addition, the qualiﬁcation process included eval-
ating the impact of impurities commonly encountered alongside
he carbohydrate product as well as a diverse library of polysaccha-
ides.
Novel procedures were described to simplify methods and facil-
tate automation. A phenol sulphuric acid assay was optimized for
igh throughput quantitation of mono-, di-, and poly-saccharides.
he assay requires only 25 L of sample and involves no heat-
ng steps that can stymie automation. The described procedure
lso reduces the quantities of hazardous chemicals such as phe-
ol and sulphuric acid, requiring only 150 L total per sample. A
inear range of approximately 2 logs (e.g. glucose: 8–1000 g/mL)
as observed for every tested carbohydrate, with the actual range
erived from the speciﬁc composition of reactive sugars present.
he precision of the described assay was found to be 10%. The
yroGeneTM assay was simpliﬁed to a single measurement while
emoving a heated incubation step. This modiﬁed assay was
emonstrated to be robust for the determination of the range
f endotoxin concentrations present in samples drawn from har-
est, clariﬁcation, and most polishing unit operations. For protein
uantiﬁcation, the BCA assay was shown to be superior for the
etermination of protein concentration while the Bradford assay
ffers an adequate assay when speciﬁc interferences exclude the
CA assay. Using the differential signal from these two protein
ssays, a method was conceived and demonstrated to be capable
f estimating the amount of a reducing sugar present. When nei-
her ﬁne accuracy nor precision is required, this method may  offer a
ess experimentally demanding and more streamlined approach for
educing sugar determination than the PHS assay. In conjunction
ith well-established methods for quantifying DNA, these methods
omprise the core analytical techniques needed to support puriﬁ-
ation process development.
[
[ (2014) 2819–2828 2827
The described suite of analytics enables the rapid quantita-
tion of key molecular classes in a microplate-based format that is
amenable to automation. The deployment of these analytics will
enable the development of high throughput processing platforms
to speed the development of polysaccharide manufacturing pro-
cesses.
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